Zoë Hyde

Zoë Hyde

Auto-generated profile, based on publicly available information

Zoë Hyde

Western Australian Centre for Health and Ageing, Medical School University of Western Australia Perth Western Australia Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ZHZoë Hyde
Zoë Hyde
LFLeon Flicker
Leon Flicker
OAOsvaldo P. Almeida
Osvaldo P. Almeida
GHGraeme J. Hankey
Graeme J. Hankey
KMKieran A. McCaul
Kieran A. McCaul
BYBu B. Yeap
Bu B. Yeap
Context: The prevalence of frailty increases, whereas testosterone decreases, as men age. Low testosterone may be a risk factor for development of this syndrome. Objective: Our objective was to determine whether testosterone levels are associated with frailty. Design: We conducted a prospective cohort study. Setting and Participants: Between 2001 and 2004, frailty was assessed in 3616 community-dwelling men aged 70–88 yr. Frailty was reassessed in 1586 men aged 76–93 yr in 2008–2009. Main Outcome Measures: Frailty was assessed with the FRAIL scale, comprising five domains: fatigue, difficulty climbing a flight of stairs, difficulty walking more than 100 m, more than five illnesses present, or weight loss greater than 5%. Testosterone, SHBG, and LH were assayed at baseline. Free testosterone was calculated using mass action equations. Results: At baseline, 15.2% of men (n = 548) were frail (at least three deficits), increasing to 23.0% (n = 364) at follow-up. At baseline, each 1 sd decrease in total or free testosterone level was associated with increased odds of frailty [odds ratio (OR) = 1.23; 95% confidence interval (CI) = 1.11–1.38, and OR = 1.29; 95% CI = 1.15–1.44 for total and free testosterone, respectively]. Lower LH was associated with reduced odds of frailty (OR = 0.88; 95% CI = 0.81–0.95). Adjustments were made for age, body mass index, smoking, diabetes, social support, and other covariates. At follow-up, only lower free testosterone levels (OR = 1.22; 95% CI = 1.05–1.42) predicted frailty. Conclusions: Lower free testosterone was independently associated with frailty at baseline and follow-up. Randomized trials should explore whether testosterone therapy can prevent the development of frailty.

1 July 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
BYBu B. Yeap
Bu B. Yeap
ZHZoë Hyde
Zoë Hyde
OAOsvaldo P. Almeida
Osvaldo P. Almeida
PNPaul E. Norman
Paul E. Norman
SCS. A. Paul Chubb
S. A. Paul Chubb
GHGraeme J. Hankey
Graeme J. Hankey
Context: Lower circulating testosterone concentrations are associated with metabolic syndrome, type 2 diabetes, carotid intima-media thickness, and aortic and lower limb arterial disease in men. However, it is unclear whether lower testosterone levels predict major cardiovascular events. Objective: We examined whether lower serum testosterone was an independently significant risk factor for symptomatic cerebrovascular events in older men. Design: This was a prospective observational study with median follow-up of 3.5 yr. Setting: Community-dwelling, stroke-free older men were studied. Participants: A total of 3443 men at least 70 yr of age participated in the study. Main Outcome Measures: Baseline serum total testosterone, SHBG, and LH were assayed. Free testosterone was calculated using mass action equations. Incident stroke or transient ischemic attack (TIA) was recorded. Results: A first stroke or TIA occurred in 119 men (3.5%). Total and free testosterone concentrations in the lowest quartiles (<11.7 nmol/liter and <222 pmol/liter) were associated with reduced event-free survival (P = 0.014 and P = 0.01, respectively). After adjustment including age, waist-hip ratio, waist circumference, smoking, hypertension, dyslipidemia, and medical comorbidity, lower total testosterone predicted increased incidence of stroke or TIA (hazard ratio = 1.99; 95% confidence interval, 1.33–2.99). Lower free testosterone was also associated (hazard ratio = 1.69; 95% confidence interval, 1.15–2.48), whereas SHBG and LH were not independently associated with incident stroke or TIA. Conclusions: In older men, lower total testosterone levels predict increased incidence of stroke or TIA after adjusting for conventional risk factors for cardiovascular disease. Men with low-normal testosterone levels had increased risk. Further studies are warranted to determine whether interventions that raise circulating testosterone levels might prevent cerebrovascular disease in men.

3 March 2008 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
PNPaul Norman
Paul Norman
LFLeon Flicker
Leon Flicker
OAOsvaldo P. Almeida
Osvaldo P. Almeida
GHGraeme J Hankey
Graeme J Hankey
ZHZoë Hyde
Zoë Hyde
KJKonrad Jamrozik
Konrad Jamrozik
The Health In Men Study (HIMS) arose out of a population-based randomized trial of screening for abdominal aortic aneurysms (AAAs) conducted in Perth, Western Australia in 1996–99.1,2 Only men aged 65 years and over were recruited into the trial as AAAs are uncommon below this age and are six times more common in men than women. The aim of the trial was to assess whether screening reduced mortality from AAA. Secondary outcomes included assessments of the impact of screening on all-cause mortality and quality of life3 and a study of the rates of expansion of screen-detected AAAs.4

1 January 2012 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ZHZoë Hyde
Zoë Hyde
PNPaul E. Norman
Paul E. Norman
LFLeon Flicker
Leon Flicker
GHGraeme J. Hankey
Graeme J. Hankey
OAOsvaldo P. Almeida
Osvaldo P. Almeida
BYBu B. Yeap
Bu B. Yeap
Context: Low testosterone is associated with all-cause mortality, but the relationship with cause-specific mortality is uncertain. Objective: Our objective was to explore associations between testosterone and its related hormones and cause-specific mortality. Design: This was a population-based cohort study. Setting and Participants: Demographic and clinical predictors of mortality, and testosterone, SHBG, and LH were measured from 2001–2004 in 3637 community-dwelling men aged 70–88 yr (mean, 77 yr). Main Outcome Measure: Cause of death was obtained via electronic record linkage until December 31, 2008. Results: During a mean follow-up period of 5.1 yr, there were 605 deaths. Of these, 207 [34.2%; 95% confidence interval (CI) = 30.4–38.1%] were due to cardiovascular disease (CVD), 231 to cancer (38.2%; 95% CI = 34.3–42.1%), 130 to respiratory diseases (21.5%; 95% CI = 18.2–24.8%), and 76 to other causes (12.6%; 95% CI = 9.9–15.2%). There were 39 deaths attributable to both cancer and respiratory diseases. Lower free testosterone (hazard ratio = 1.62; 95% CI = 1.20–2.19, for 100 vs. 280 pmol/liter), and higher SHBG and LH levels were associated with all-cause mortality. In cause-specific analyses, lower free testosterone (sub-hazard ratio = 1.71; 95% CI = 1.12–2.62, for 100 vs. 280 pmol/liter) and higher LH predicted CVD mortality, while higher SHBG predicted non-CVD mortality. Higher total testosterone and free testosterone levels (sub-hazard ratio = 1.96; 95% CI = 1.14–3.36, for 400 vs. 280 pmol/liter) were associated with mortality from lung cancer. Conclusions: Low testosterone predicts mortality from CVD but is not associated with death from other causes. Prevention of androgen deficiency might improve cardiovascular outcomes but is unlikely to affect longevity otherwise.

1 May 2007 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
BYBu B. Yeap
Bu B. Yeap
OAOsvaldo P. Almeida
Osvaldo P. Almeida
ZHZoë Hyde
Zoë Hyde
PNPaul E Norman
Paul E Norman
SCS A Paul Chubb
S A Paul Chubb
LFLeon Flicker
Leon Flicker
Objective: An age-related decline in serum total and free testosterone concentration may contribute to ill health in men, but limited data are available for men > 70 years of age. We sought to determine the distribution and associations of reduced testosterone concentrations in older men. Design: The Health in Men Study is a community-representative prospective cohort investigation of 4263 men aged ≥ 70 years. Cross-sectional hormone data from 3645 men were analysed. Methods: Early morning sera were assayed for total testosterone, sex hormone binding globulin (SHBG) and LH. Free testosterone was calculated using the Vermeulen method. Results: Mean (± s.d.) serum total testosterone was 15.4 ± 5.6 nmol/l (444 ± 162 ng/dl), SHBG 42.4 ± 16.7 nmol/l and free testosterone 278 ± 96 pmol/l (8.01 ± 2.78 ng/dl). Total testosterone correlated with SHBG (Spearman’s r = 0.6, P < 0.0001). LH and SHBG increased with age (r = 0.2, P < 0.0001 for both). Instead of declining, total testosterone increased marginally (r = 0.04, P = 0.007) whilst free testosterone declined with age (r = −0.1, P < 0.0001). Free testosterone was inversely correlated with LH (r = −0.1, P < 0.0001). In multivariate analyses, increasing age, body mass index (BMI) and LH were associated with lower free testosterone. Conclusions: In men aged 70–89 years, modulation of androgen action may occur via an age-related increase in SHBG and reduction in free testosterone without a decline in total testosterone concentration. Increasing age, BMI and LH are independently associated with lower free testosterone. Further investigation would be required to assess the clinical consequences of low serum free testosterone, particularly in older men in whom total testosterone may be preserved.

1 October 2009 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
BYBu B. Yeap
Bu B. Yeap
SCS A Paul Chubb
S A Paul Chubb
ZHZoë Hyde
Zoë Hyde
KJKonrad Jamrozik
Konrad Jamrozik
GHGraeme J Hankey
Graeme J Hankey
PNPaul E Norman
Paul E Norman
Objective: Insulin resistance is associated with metabolic syndrome and type 2 diabetes, representing a risk factor for cardiovascular disease. This relationship may be modulated to some extent by age-related changes in sex hormone status. We examined whether lower testosterone or sex hormone-binding globulin (SHBG) levels in older men are associated with insulin resistance independently of measures of central obesity.Design: Cross-sectional analysis of 2470 community-dwelling non-diabetic men aged ≥70 years.Methods: Age, body mass index (BMI) and waist circumference were measured. Early morning sera were assayed for total testosterone, SHBG, LH and insulin levels. Free testosterone was calculated using mass action equations, and insulin resistance was assessed using a homeostatic model (HOMA2-IR).Results: Total testosterone, free testosterone and SHBG declined progressively across increasing quintiles of HOMA2-IR (all P<0.001) and correlated inversely with log HOMA2-IR (r=−0.27, −0.14 and −0.24 respectively, all P<0.001). After adjusting for age, BMI, waist circumference, high-density lipoprotein and triglyceride levels, total testosterone was independently associated with log HOMA2-IR (β=0.05, P<0.001), while SHBG was not. Serum total testosterone <8 nmol/l was associated with HOMA2-IR in the highest quintile (odds ratio (OR) 1.67, 95% confidence interval (CI) 1.02–2.73) as was total testosterone ≥8 and <15 nmol/l (OR 1.29, 95% CI 1.03–1.63).Conclusions: In older men, lower total testosterone is associated with insulin resistance independently of measures of central obesity. This association is seen with testosterone levels in the low to normal range. Further studies are needed to evaluate interventions that raise testosterone levels in men with reduced insulin sensitivity.